 Here are 5 potential future research ideas based on the paper:

1. Conduct a prospective study to validate the prognostic value of the CHA2DS2-VASc score for predicting mortality and adverse events in IPF patients without atrial fibrillation. This would provide stronger evidence than the retrospective study design. 

2. Evaluate whether treatment interventions guided by the CHA2DS2-VASc score (e.g. more aggressive cardioprotective medications for high risk patients) improve outcomes in IPF patients. This could demonstrate the clinical utility of the score.

3. Assess myocardial strain parameters by speckle tracking echocardiography and determine if they add incremental prognostic value over the CHA2DS2-VASc score alone in IPF patients. This could identify better echocardiographic predictors.  

4. Evaluate the prognostic utility of inflammatory biomarkers like KL-6, SP-A/D, and MMP-7 and compare or combine them with the CHA2DS2-VASc score for risk stratification in IPF. This could identify optimal biomarkers.

5. Validate the CHA2DS2-VASc score in IPF populations from multiple centers internationally to determine generalizability across geographic regions. This could strengthen the broad applicability of the score.